bbc– Under-30s in the UK are to be offered an alternative Covid vaccine to the AstraZeneca jab due to the evidence linking it to rare blood clots.
The recommendation comes after a review by the UK drugs regulator found that by the end of March 79 people had suffered rare blood clots after vaccination – 19 of whom had died.
The regulator said this was not proof the jab had caused the clots.
But it said the link was getting firmer.
- How do you weigh up the risks of the AstraZeneca vaccine?
The review by the Medicines and Healthcare products Regulatory Agency (MHRA) found:
- The 79 cases and 19 deaths occurred after 20 million doses were administered – giving a risk of about four in one million of developing a blood clot, and one in a million of dying
- Nearly two-thirds of the cases of rare clots were seen in women
- The people who died were aged between 18 and 79, with three of them aged under 30
- All the recorded cases occurred after the first dose, although the lower number of second doses meant it was not possible to draw any conclusions from this
Meanwhile, the EU’s medicines regulator says unusual blood clots should be listed as a possible very rare side effect of the AstraZeneca jab, but that the benefits outweighed the risks. Some European countries have restricted the vaccine’s use.
The World Health Organization said the link between the vaccine and blood clots was “plausible” but not confirmed, adding that the clotting incidents were “very rare” among nearly 200 million people who have received the jab worldwide.
Analysis: Should we be worried about a one-in-a-million risk?
No treatment or vaccine is risk free. The key question is whether it does more good than harm.
Wednesday’s update once again demonstrates the AstraZeneca vaccine does – even if you assume it’s causing these clots, which has not been proven yet.
The risk of dying from one of them following vaccination is incredibly small – about one in a million.
By contrast, Covid kills one in eight people who are infected over the age of 75, and one in 1,000 infected in their 40s among those who develop symptoms.
It is less clear cut for those under 30, who are much less likely to die of Covid – although the AstraZeneca vaccine still presents more benefit than risk.
However, other vaccines may be an even better bet.
The risk might look worrying, but it is actually very low, and usually we don’t think about things just in terms of risk.
For example, travelling 250 miles in a car also carries with it a one-in-a-million chance of dying in an accident. How many think about that when they get behind the wheel?
Health Secretary Matt Hancock said the UK’s review confirmed that the Oxford-AstraZeneca jab is “safe, effective and the benefits far outweigh the risks for the vast majority of adults”.
Prime Minister Boris Johnson said the AstraZeneca vaccine had “already saved thousands of lives” and the new advice should ensure people of all ages “continue to have full confidence in vaccines”.
Labour leader Sir Keir Starmer also urged people to “trust in our doctors and scientists” and said he was looking forward to receiving his second AstraZeneca dose.
AstraZeneca said both the MHRA and the EMA reviews reaffirmed that the benefits of the vaccine “continue to far outweigh the risks”.
The UK reported a further 45 deaths from Covid-19 and another 2,763 confirmed cases on Wednesday. Vaccinations remained low after the Easter weekend, with 186,793 second doses administered and 85,227 first doses.
June Raine, chief executive of the MHRA, said the side-effects of the AstraZeneca vaccine were “extremely rare” – and more work was going to identify if the vaccine was definitely causing the clots.
“The balance of benefits and known risks is still very favourable for the majority of people,” she said.
But she said for younger age groups it was more “finely balanced”.
She added: “The public’s safety is at the forefront of our minds.”
Dr Raine said there was a “reasonably plausible” link between the vaccine and the blood clots.
The review prompted the UK government’s vaccine advisory group, the JCVI, to recommend that people aged 18 to 29 be offered an alternative vaccine where available.
Professor Lim Wei Shen, of the JCVI, said the move was being made “out of the utmost caution rather than because we have any serious safety concerns”.